pyrus nivalis - Gardening Tips
The announcement of Nivalis Therapeutics, Inc.’s NVLS merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors. Nivalis fell more than 10% ...
Understanding the Context
FierceBiotech: Nivalis fails phase 2 cystic fibrosis test, but vows to continue on Nivalis saw more than half its value wiped out after hours last night in reaction to the news that its cystic fibrosis (CF) candidate did not hit its targets, leaving its future hanging in the balance ... Nivalis fails phase 2 cystic fibrosis test, but vows to continue on Fox Business: Nivalis' Stock Loses Half Its Value After Failed Trial Prompts Analyst Downgrades Shares of Nivalis Therapeutics Inc. plunged 53% toward a record low in premarket trade Tuesday, after a Phase 2 trial of its cystic fibrosis treatment failed its primary endpoint. Although the two ...
Image Gallery
Key Insights
Nivalis' Stock Loses Half Its Value After Failed Trial Prompts Analyst Downgrades Alpine Immune Sciences is set to merge with Nivalis Therapeutics and snag itself a stock listing in the process. The agreement puts Mitch Gold back at the helm of a public biotech for the first time ...